Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women

Part of paid clinical trials in Canfield, Ohio.

Sponsor
Nutrition 21, Inc.
Study ID
NCT07402382
Status
Recruiting
Apply to this trial

Conditions

  • Glucose Monitoring, Continuous
  • Peri-menopausal Women
  • Post-menopause
  • Whole Body Protein Metabolism

Eligibility Criteria

Sex
FEMALE
Age
40 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Amylopectin-chromium blend — DIETARY_SUPPLEMENT
    Amylopectin-chromium blend, 2 g
  • Concentrated Amylopectin-chromium blend — DIETARY_SUPPLEMENT
    Amylopectin-chromium blend in a concentrated format (100 mg)
  • Placebo — DIETARY_SUPPLEMENT
    Amylopectin, 2 g

Study Details

The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period. The main questions the study aims to answer are: * Does the use of an amylopectin chromium blend in peri- and post-menopausal women help to support positive protein balance * Can the affect be achieved using a concentrated dose Researchers will compare the nutritional supplement to a placebo (amylopectin alone) to see if the amylopectin chromium blend can promote positive protein balance. A concentrated dose of the supplement will also be evaluated for comparative effectiveness. Participants will: * Consume the nutritional supplement (standard or concentrated dose) or placebo acutely after a short resistance exercise bout * Complete four in-person visits, including the single-day intervention Results from this research may help guide future nutritional strategies to support healthy aging, muscle function, and overall metabolic health.

Key Dates

Start date
Nov 1, 2025
Status verified
Apr 2026
Primary completion
Jun 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Placebo
    Placebo
  • Experimental: Active 1
    Standard dose
  • Experimental: Active 2
    Concentrated dose

Primary Outcome Measure

Whole-Body Protein Turnover (Protein Synthesis and Breakdown) [ Time Frame: 24 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Center for Applied Health SciencesCanfieldOhio44406-

Find similar trials in Canfield, OH

By research site
The Center for Applied Health Sciences· Canfield, OH

Related Studies